AllianceBernstein
RLAY icon

AllianceBernstein’s Relay Therapeutics RLAY Stock Holding History

AllianceBernstein’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.8M Buy
4,095,600
+3,950,349
+2,720% +$57.3M 0.01% 685
2026
Q1 		$1.23M Hold
145,251
– – ﹤0.01% 2252
2025
Q4 		$1.23M Hold
145,251
– – ﹤0.01% 2256
2025
Q3 		$758K Hold
145,251
– – ﹤0.01% 2471
2025
Q2 		$503K Sell
145,251
-23,030
-14% -$68.5K ﹤0.01% 2637
2025
Q1 		$441K Buy
168,281
+30,000
+22% +$118K ﹤0.01% 2601
2024
Q4 		$570K Hold
138,281
– – ﹤0.01% 2580
2024
Q3 		$979K Sell
138,281
-424,574
-75% -$3.17M ﹤0.01% 2342
2024
Q2 		$3.67M Buy
562,855
+24,252
+5% +$166K ﹤0.01% 1625
2024
Q1 		$4.47M Buy
538,603
+400,322
+289% +$3.91M ﹤0.01% 1506
2023
Q4 		$1.52M Sell
138,281
-1,103,194
-89% -$9.31M ﹤0.01% 2074
2023
Q3 		$10.4M Sell
1,241,475
-629,555
-34% -$6.77M ﹤0.01% 1068
2023
Q2 		$23.5M Buy
1,871,030
+385,116
+26% +$4.79M 0.01% 800
2023
Q1 		$24.5M Sell
1,485,914
-204,107
-12% -$3.66M 0.01% 763
2022
Q4 		$25.2M Buy
1,690,021
+286,596
+20% +$5.49M 0.01% 769
2022
Q3 		$31.4M Sell
1,403,425
-469,839
-25% -$10.3M 0.02% 692
2022
Q2 		$31.4M Buy
1,873,264
+64,314
+4% +$1.38M 0.01% 712
2022
Q1 		$54.1M Buy
1,808,950
+63,323
+4% +$1.54M 0.02% 580
2021
Q4 		$53.6M Buy
1,745,627
+391,364
+29% +$12.4M 0.02% 602
2021
Q3 		$42.7M Buy
1,354,263
+109,498
+9% +$3.69M 0.02% 662
2021
Q2 		$45.5M Buy
1,244,765
+191,474
+18% +$6.31M 0.02% 649
2021
Q1 		$36.4M Buy
1,053,291
+232,522
+28% +$10.1M 0.02% 714
2020
Q4 		$34.1M Buy
820,769
+118,608
+17% +$5.36M 0.02% 691
2020
Q3 		$29.9M Buy
+702,161
New +$26.8M 0.02% 678

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

AllianceBernstein's RLAY Position: Q2 2026 in Review

AllianceBernstein increased its Relay Therapeutics (RLAY) stake by 2,720% in Q2 2026, buying an estimated $57.3M and bringing the position to 4,095,600 shares worth $40.8M. The position accounts for 0.01% of the portfolio, ranked #685.

AllianceBernstein first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. The position peaked at $54.1M in Q1 2022. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • AllianceBernstein held 4,095,600 shares of Relay Therapeutics worth $40.8M as of Q2 2026.
  • AllianceBernstein bought 3,950,349 Relay Therapeutics shares in Q2 2026, an estimated $57.3M.
  • Relay Therapeutics made up 0.01% of AllianceBernstein's portfolio in Q2 2026, its #685 holding.
  • AllianceBernstein first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • AllianceBernstein's Relay Therapeutics position peaked at $54.1M in Q1 2022.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.